Animal models of VAP

D. Bruno, J. García-Morato, C.M. Luna

Source: Eur Respir Monogr 2011; 53: 98-112
Disease area: Respiratory critical care, Respiratory infections

Congress or journal article abstractFull text journal article

Abstract

Summary

Animal models of ventilator-associated pneumonia (VAP) represent a unique scenario for the study of the different aspects of human VAP. Several years of investigation have yielded important information regarding: the understanding of lung and systemic inflammatory responses to pneumonia and potential therapeutic modulation; the different diagnostic sampling methods with the advantage of having a gold standard for microbiology and histopathology of lung samples; clinical efficacy of intravenous and aerosolised antimicrobials and their pharmacokinetic parameters in lung disease infections; how pneumonia affects the different patterns and modes of mechanical ventilation; and the study of preventive measures in VAP. This chapter focuses on: the basic principles of animal model VAP preparation; how the above-mentioned aspects are studied; and how more realistic results are produced and how their translation into clinical practice can occur.



Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Bruno, J. García-Morato, C.M. Luna. Animal models of VAP. Eur Respir Monogr 2011; 53: 98-112

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Animal models of ventilator-associated pneumonia
Source: Eur Respir J 2009; 33: 182-188
Year: 2009



Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors
Source: Eur Respir J 2010; 35: 598-615
Year: 2010



What lessons have been learnt from animal models of MRSA in the lung?
Source: Eur Respir J 2010; 35: 198-201
Year: 2010



Aetiopathogenesis of VAP revisited
Source: Eur Respir Mon 2011; 53: 1-10
Year: 2011


Experimental Pseudomonas aeruginosa pneumonia: evaluation of the associated inflammatory response
Source: Eur Respir J 2007; 30: 1167-1172
Year: 2007



What is MRSA?
Source: Eur Respir J 2009; 34: 1190-1196
Year: 2009



Broad spectrum of virulence of pseudomonas aeruginosa clones characterized in a murine airway infection model
Source: Annual Congress 2013 –Bacterial, fungal and mycobacterial infections
Year: 2013


Early mortality in patients with community-acquired pneumonia: causes and risk factors
Source: Eur Respir J 2008; 32: 733-739
Year: 2008



MRSA as a cause of lung infection including airway infection, community-acquired pneumonia and hospital-acquired pneumonia
Source: Eur Respir J 2009; 34: 1470-1476
Year: 2009



Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia
Source: Eur Respir J 2007; 29: 548-560
Year: 2007



An experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated piglets
Source: Eur Respir J 2010; 36: 901-906
Year: 2010



Diagnostic challenge in community-acquired pneumonia and hospital-acquired pneumonia: risk factors and diagnostic methods for methicillin resistant Staphylococcus aureus
Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen?
Year: 2006


Community-acquired pneumonia in Europe: causative pathogens and resistance patterns
Source: Eur Respir J 2002; 20: 20S-27S
Year: 2002



Community-acquired pneumonia due to S. aureus
Source: Annual Congress 2011 - Aetiology, diagnosis and outcomes in community-acquired pneumonia
Year: 2011

Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia
Source: Eur Respir J 2009; 34: 1148-1158
Year: 2009



Human airway epithelial cell response to Pseudomonas aeruginosa virulence factors preceded or not by Staphylococcus aureus
Source: Eur Respir J 2006; 28: Suppl. 50, 191s
Year: 2006

The role of the type 3 secretion system effector protein ExoY during pathogenesis of pseudomonas aeruginosa lung infections
Source: International Congress 2014 – Pathogenesis and mechanisms of respiratory infections
Year: 2014

Streptococcus pneumoniae resistance pattern and its clinical implications
Source: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections
Year: 2006



Mesenchymal stem cells enhance bacterial clearance of streptococcal pneumoniae and pseudomonas aeruginosa in the lung
Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections
Year: 2016

Peculiarities of community-acquired pneumonia course, caused by multiresistant strains of S. pneumoniae
Source: Eur Respir J 2006; 28: Suppl. 50, 165s
Year: 2006